Janssen Search
Search results
Nauman Shah
NAUMAN SHAH GLOBAL HEAD JANSSEN BUSINESS DEVELOPMENT Nauman Shah is Global Head, Janssen Business Development. In this role, Nauman leads the Janssen Business Development organization in the identification, evaluation, execution, integration and ...
Leading Innovation in Neuroscience
Leading Innovation in Neuroscience Nov 22, 2021 Subhead: Lorem ipsum dolor sit amet, consectetuer adipiscing elit Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Phasellus hendrerit. Pellentesque aliquet nibh nec urna. In nisi neque, aliquet vel ...
Johnson & Johnson reports positive topline results for nipocalimab from a Phase 3 pivotal study in generalized myasthenia gravis (gMG) and a Phase 2 study in Sjögren’s Disease (SjD)
Feb 05, 2024 United States Nipocalimab showed clinical efficacy in gMG, a chronic debilitating autoantibody disease where significant unmet patient need exists for efficacious, safe therapies that offer sustained disease control Nipocalimab is the first ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery
May 03, 2024 Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery SAN ANTONIO, May 3, ...
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research
BeneVir’s Oncolytic Virus Technology Offers a Unique Opportunity to Strengthen Janssen’s Immunotherapy Research Nov 20, 2018 At a small company in Rockville, Maryland, a handful of researchers are working on viruses that can be tailored to avoid ...
How We Can Predict Colorectal Cancer Development and Treat it Earlier Than Ever
How We Can Predict Colorectal Cancer Development and Treat it Earlier Than Ever Twenty-one years ago, when President Bill Clinton declared March as National Colorectal Cancer Awareness Month, he highlighted the importance of early detection in improving ...
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Jun 28, 2024 Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers 1 The CHMP’s recommendation is based on results from Cohort 1 of ...
U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Jan 19, 2024 United States BALVERSA ® is the First and Only Targeted Therapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Susceptible Fibroblast Growth Factor Receptor Alterations Phase 3 THOR Study Showed a 36 Percent ...
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Feb 20, 2024 United States Biweekly dosing with TECVAYLI ®, the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility HORSHAM, Pa., February 20, 2024 – Johnson & Johnson announced today that the U.S. Food and ...
Joaquin Duato
JOAQUIN DUATO VICE CHAIRMAN OF THE EXECUTIVE COMMITTEE JOHNSON & JOHNSON Joaquin Duato is a globally-experienced, values-driven health care business leader and currently Vice Chairman of the Executive Committee of Johnson & Johnson, the world’s ...